---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-024269"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2026-06-05T20:09:22+00:00"
generated_at: "2026-06-05T20:20:56.042135+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Grace Therapeutics VP of Clinical Ops departing, will consult at $250/hr for NDA work

## Summary
- Carrie D'Andrea, VP of Clinical Operations, to cease employment effective June 5, 2026.
- She entered a 12-month consulting agreement at $250/hour for clinical development and NDA-related services.
- Stock option awards will continue to vest during the consulting term and remain exercisable for 90 days after termination.
- Severance benefits per November 2025 letter agreement, conditioned on release of claims and non-compete/non-solicitation covenants.

## SEC filing metadata
- accession: 0001140361-26-024269
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2026-06-05T20:09:22+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036126024269/0001140361-26-024269-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036126024269/ef20075612_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-024269
- JSON: https://secwatch.observer/filing/0001140361-26-024269.json
- Plain text: https://secwatch.observer/filing/0001140361-26-024269.txt

## Key facts
- Executive change
  Carrie D'Andrea departed as Vice President of Clinical Operations at Grace Therapeutics, Inc..
  - Action: ceased serving as Vice President of Clinical Operations
  - Role: Vice President of Clinical Operations
  source text: Carrie D’Andrea will cease serving as Vice President of Clinical Operations of the Company and will no longer be employed by the Company effective June 5, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000114036126024269/0001140361-26-024269-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.